The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Sylvia K. Haas

Klinikum rechts der Isar der Technischen Universität München

Germany

[email]@lrz.tum.de

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Klinikum rechts der Isar der Technischen Universität München, Germany. 2009
  • Institut für Experimentelle Onkologie und Therapieforschung, Technische Universität München, Munich, Germany. 2002 - 2009

References

  1. New anticoagulants - towards the development of an "ideal" anticoagulant. Haas, S. VASA (2009) [Pubmed]
  2. Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme. Haas, S. Eur. J. Haematol. (2009) [Pubmed]
  3. New oral Xa and IIa inhibitors: updates on clinical trial results. Haas, S. J. Thromb. Thrombolysis (2008) [Pubmed]
  4. Primary prevention of venous thromboembolism in long-term care: identifying and managing the risk. Haas, S., Spyropoulos, A.C. Clin. Appl. Thromb. Hemost. (2008) [Pubmed]
  5. New anticoagulants: from bench to bedside. Haas, S., Schellong, S. Hamostaseologie (2007) [Pubmed]
  6. Idiopathic venous thrombosis. Long-term anticoagulation therapy? Yes. Haas, S. Hamostaseologie (2006) [Pubmed]
  7. The use of a surgical patch coated with human coagulation factors in surgical routine: a multicenter postauthorization surveillance. Haas, S. Clin. Appl. Thromb. Hemost. (2006) [Pubmed]
  8. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial). Haas, S., Breyer, H.G., Bacher, H.P., Fareed, J., Misselwitz, F., Victor, N., Weber, J. Int. Angiol (2006) [Pubmed]
  9. New anticoagulant drugs: a critical perspective. Haas, S. Curr. Hematol. Rep. (2005) [Pubmed]
  10. Oral direct thrombin inhibition: an effective and novel approach for venous thromboembolism. Haas, S. Drugs (2004) [Pubmed]
  11. Medical indications and considerations for future clinical decision making. Haas, S. Thromb. Res. (2003) [Pubmed]
  12. Venous thromboembolism in medical patients--the scope of the problem. Haas, S. Semin. Thromb. Hemost. (2003) [Pubmed]
  13. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes. Haas, S. Semin. Vasc. Med (2003) [Pubmed]
  14. Venous thromboembolic risk and its prevention in hospitalized medical patients. Haas, S.K. Semin. Thromb. Hemost. (2002) [Pubmed]
 
WikiGenes - Universities